| Bioactivity | Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells[1]. |
| Target | CD2 subset 1 |
| Invitro | Azintuxizumab vedotin (ABBV-838) 是一种 ADC，由人源化重组免疫球蛋白 G1κ 组成，针对 CD2 subset 1 (CS1，也称为 SLAMF7) 的独特表位，通过缬氨酸-瓜氨酸连接子与细胞毒性单甲基 auristatin E (MMAE) 结合[1]。Azintuxizumab vedotin 对表达 CS1 的癌细胞显示出强大的细胞毒活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Azintuxizumab vedotin 相关抗体: |
| In Vivo | Azintuxizumab vedotin (ABBV-838) 在使用人骨髓瘤异种移植的小鼠模型中显示单药抗肿瘤活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 1826819-58-2 |
| Appearance | 液体 |
| Transport | Shipping with dry ice. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Vij R, et al. First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clin Cancer Res. 2020 May 15;26(10):2308-2317. |